ReviewThe Korean journal of internal medicine2018
Vibrio vulnificus infection: a persistent threat to public health.
Review in The Korean journal of internal medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Predicting the Global Distribution of Vibrio vulnificus Under Changing Climate Scenarios.EcoHealth · 2026Pooled it
- VEXAS Syndrome with Vibrio vulnificus Sepsis during Treatment with Tocilizumab.Internal medicine (Tokyo, Japan) · 2026Article
- Bisphenol F-Associated Repeated Breeding Syndrome in Cows: Epidemiological Evidence and Protective Effects of Phillyrin Against Granulosa Cell Injury.Veterinary sciences · 2026Article
- Examining pathogenicApplied and environmental microbiology · 2026Article
- Clinical characteristics, treatment outcomes, and predictors of early mortality in Vibrio vulnificus infection in Eastern Thailand: A 6.5-year multicenter cohort study.PLoS neglected tropical diseases · 2026Article
- Quantifying Vibrio Infection Risks From Beach Recreation Along U.S. Eastern Seaboard in Year 2100.GeoHealth · 2026Article
- Article
- Immunogenicity of Adalimumab in Bacterial Molecular Mimicry: In Silico Analysis.JMIR bioinformatics and biotechnology · 2025Article
- A systematic review of the avian antibody (IgY) therapeutic effects on human bacterial infections over the decade.Antibody therapeutics · 2025Review
- Early diagnosis and application of hemopurification combined with antibiotic therapy and surgical debridement for successful treatment of a child with Vibrio vulnificus necrotizing fasciitis and septic shock: a case report.BMC infectious diseases · 2025Article
- Genome-wide phenotypic profiling of transcription factors and identification of novel targets to control the virulence of Vibrio vulnificus.Nucleic acids research · 2025Article
- Non-cholera Vibrio spp. invasive infections in the summer following May 2023 flood disaster in Romagna, Italy: a case series.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Article
- Haemolysins are essential to the pathogenicity of deep-seaiScience · 2024Article
- [Epidemiological Characteristics of Cases and Deaths ofJugan geon-gang gwa jilbyeong · 2024Article
- Necrotizing fasciitis in a 44-year-old woman caused byCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2024Article
- Article
- Increased incidence of vibriosis in Maryland, U.S.A., 2006-2019.Environmental research · 2024Article
- Vibrio vulnificus pneumonia with multiorgan failure: a case report and review of the literature.Journal of medical case reports · 2023Review
- Distribution, Prevalence, and Antibiotic Susceptibility Profiles of Infectious NoncholeraJournal of tropical medicine · 2023Article
- Case Report: First case of HIV, hepatitis B, hepatitis C, and Vibrio vulnificus coinfection.Frontiers in cellular and infection microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Vibrio vulnificus is a gram-negative bacterium that can cause serious, potentially fatal infections. V. vulnificus causes three distinct syndromes: an overwhelming primary septicemia caused by consuming contaminated seafood, wound infections acquired when an open wound is exposed to contaminated warm seawater, and gastrointestinal tract-limited infections. Case-fatality rates are higher than 50% for primary septicemia, and death typically occurs within 72 hours of hospitalization. Risk factors for V. vulnificus infection include chronic liver disease, alcoholism, and hematological disorders. When V. vulnificus infection is suspected, appropriate antibiotic treatment and surgical interventions should be performed immediately. Third-generation cephalosporin with doxycycline, or quinolone with or without third-generation cephalosporin, may be potential treatment options for patients with V. vulnificus infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.